Novel application of ceruloplasmin in treatment of multiple sclerosis

A technology for ceruloplasmin and multiple sclerosis, applied in peptide/protein components, medical preparations containing active ingredients, allergic diseases, etc., can solve the heavy economic burden and mental stress of patients and their families, and the unreachable Radical effect and other issues

Pending Publication Date: 2020-12-01
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, such drugs can only alleviate the patient's condition, but cannot achieve a radical effect, and some drugs have serious side effects, which bring heavy economic burden and mental pressure to the patient and their family

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of ceruloplasmin in treatment of multiple sclerosis
  • Novel application of ceruloplasmin in treatment of multiple sclerosis
  • Novel application of ceruloplasmin in treatment of multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Ceruloplasmin (Cp) Improves Clinical Scores of EAE Mice

[0062] Ceruloplasmin (Cp) is a complex multicomponent oxidase, in mammals, ferroportin (Fpn) converts Fe 2+ Transported out of the cell, oxidized from Cp to Fe 3+ , combined with transferrin (Tf) transported into the blood, plays an important role in the process of iron metabolism.

[0063] After 13 days of constructing the EAE model, EAE mice with different clinical scores were intraperitoneally injected with Cp (5 mg / kg, SEQ ID NO.1), injected once every other day, and injected 5 mg / kg of Cp each time, and injected 7 times in total. After the injection was completed, observe The clinical phenotype results of the mice showed that the EAE mice with clinical scores of 1 point, 2 points, 2.5 points, and 3 points were significantly improved compared with EAE+saline mice ( figure 1 , P=0.000399, Pfigure 1 , P>0.05, Data means±SEM, n=7). The above results suggest that Cp can alleviate the clinical scores of EAE mic...

Embodiment 2

[0065] Plasma ceruloplasmin improves pathological changes in EAE mice

[0066] EAE mice with a clinical score of about 3 were injected intraperitoneally with Cp (5 mg / kg), once every other day, and injected Cp 5 mg / kg each time, for a total of 7 injections. After the injection was completed, anesthesia was perfused with 4% paraformaldehyde to fix it, and it was completely removed. Paraffin sections were prepared from the entire spinal cord and cervical spinal cord, observed and analyzed by histochemical staining. The results of HE staining showed that the mice injected with Cp were significantly improved compared with the EAE mice, and the lesions were significantly reduced ( image 3 ). The above results suggest that Cp can reduce spinal cord inflammatory infiltration in EAE mice.

[0067] EAE mice with a clinical score of about 3 were injected intraperitoneally with Cp (5 mg / kg), once every other day, and injected Cp 5 mg / kg each time, for a total of 7 injections. After th...

Embodiment 3

[0072] Plasma ceruloplasmin can reduce lipid oxides in EAE mice

[0073] EAE mice with a clinical score of about 3 points were intraperitoneally injected with Cp (5 mg / kg), once every other day, and injected with Cp 5 mg / kg each time, and injected 7 times in total. The results of metal ion analysis showed that the level of iron ion in EAE mice was significantly higher than that in the control group ( Figure 6 , P=0.0115, Data are means±SEM, n=3); after Cp injection, iron ion levels were significantly decreased compared with EAE mice ( Figure 6, P=0.0156, Data are means±SEM, n=3). The above results suggest that Cp can improve iron deposition in EAE mice.

[0074] EAE mice with a clinical score of about 3 points were intraperitoneally injected with Cp (5 mg / kg), once every other day, with 5 mg / kg of Cp each time, for a total of 7 injections. The MDA level in the homogenate of spinal cord and cortical tissue was detected by the kit. The results of lipid oxide detection show...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel application of ceruloplasmin in treatment of multiple sclerosis, and relates to the field of treatment of multiple sclerosis. The invention discloses an application ofthe ceruloplasmin in preparation of a medicine for treating multiple sclerosis. Researches show that the ceruloplasmin has obvious treatment and improvement effects on experimental allergic encephalomyelitis (EAE), which indicates that the ceruloplasmin has a prospect of treating multiple sclerosis. The invention provides new drug selection and thought for the treatment of multiple sclerosis.

Description

technical field [0001] The invention relates to the field of multiple sclerosis treatment, in particular to the new application of plasma ceruloplasmin in the treatment of multiple sclerosis. Background technique [0002] Multiple sclerosis (MS), a common autoimmune disease with white matter demyelination of the central nervous system, is characterized by high morbidity, chronic disease, and susceptibility in young adults. The main clinical features are local weakness, numbness and tingling sensation of limbs; loss of vision or blurred vision; ataxia, etc. Potential pathogenic factors include genetic and environmental factors, such as autoimmune responses stimulated by chronic viral infection. However, the exact pathogenesis is unknown and there is no specific therapy. Since 1995 when interferon-beta was used to treat MS, therapeutic drugs have only been developed for anti-inflammation and immunosuppression. However, these drugs can only relieve the patient's condition, b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P25/00A61P37/02A61P29/00
CPCA61K38/1709A61P25/00A61P37/02A61P29/00
Inventor 雷鹏庹清章罗黔晋元
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap